EXACT Therapeutics’ Phase 2 trial to be presented at the 2025 AACR Special Conference

18 Sep 2025 08:00 CEST

EXACT Therapeutics’ Phase 2 trial in pancreatic cancer patients to be presented
at the 2025 AACR Special Conference on the Advances in Pancreatic Cancer
Research

Oslo, Norway, 18 September 2025. EXACT Therapeutics (Euronext Growth: EXTX), a
clinical-stage precision medicine company, is pleased to announce that a poster
on the ongoing Phase 2 ENACT trial in locally advanced pancreatic cancer
patients (NCT06850623) will be presented at the upcoming 2025 AACR Special
Conference on the Advances in Pancreatic Cancer Research—Emerging Science
Driving Transformative Solutions, which takes place during 28 September – 1
October, 2025, in Boston, Massachusetts.

The poster will be presented on the 29 September.
• Title: A phase 2 study to investigate the efficacy and safety of acoustic
cluster therapy with modified FOLFIRINOX in patients with locally advanced
pancreatic cancer
• Poster #: A068
• In collaboration with HonorHealth Research Institute, Scottsdale, AZ, United
States


The poster will be made available on the Company’s website.

About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. EXACT Therapeutics’
shares are traded on Euronext Growth Oslo (EXTX). Further information may be
found here: www.exact-tx.com

For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site